In METABRIC, when comparing the outcome of patients with PIK3CA-mut/gain versus those with PIK3CA-mut/neut tumors, we found a significantly worse recurrence-free (RFS) (p = 0.0055) and disease-specific survival (DSS) (p = 0.0026) for the PIK3CA-mut/gain group, in both unselected patients and in those with luminal A (RFS p = 0.042, DSS p = 0.07) but not luminal B BC (RFS p = 0.29, DSS p = 0.29) (Fig. 2a–c and Supplementary Fig. 3a–c). The gene discussed is PIK3CA; the disease is breast cancer.